Details

Autor(en) / Beteiligte

• Dahir, Kathryn McCrystal
• Mcginniss, Jennifer
• Mellis, Scott
• Sanchez, Robert J
• Rocco, Maja Di
• Keen, Richard
• Orcel, Philippe
• Funck-Brentano, Thomas
• Roux, Christian
• Kolta, Sami
• Madeo, Annalisa
• Bubbear, Judith S
• Tabarkiewicz, Jacek
• Szczepanek, Małgorzata
• Bachiller-Corral, Javier
• Cheung, Angela M
• Botman, Esmée
• Mukaddam, Mona Al
• Tile, Lianne
• Portal-Celhay, Cynthia
• Sarkar, Neena
• Hou, Peijie
• Forleo-Neto, Eduardo
• Rankin, Andrew J
• Economides, Aris N
• Trotter, Dinko Gonzalez
• Eekhoff, E Marelise W
• Kaplan, Frederick S
• Pignolo, Robert J

Titel

Garetosmab Reduces Flare-ups in Patients With Fibrodysplasia Ossificans Progressiva

Ist Teil von

• Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A251-A252

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, autosomal dominant disorder driven by mutations in ACVR1 that render it responsive to Activin A. FOP is characterized by progressive heterotopic ossification (HO) and distressing inflammatory events called “flare-ups.” Flare-ups can precede new HO; however, limited prospective data exists on this phenomenon. Garetosmab (GAR), an investigational human monoclonal antibody against Activin A, blocks formation of new HO in FOP. Methods: This is a post-hoc analysis of LUMINA-1 (NCT03188666) a phase 2, randomized, double-blind, placebo-controlled study, which evaluated the safety and efficacy of GAR (10 mg/kg/week IV) versus placebo (PBO) in adult patients with FOP over 28 weeks. Patient-reported flare-ups were collected via a patient diary and severity level was reported as mild, moderate or severe. Clinician-reported flare-ups were collected as adverse events in the trial. HO lesions were imaged by 18F-NaF positron emission tomography (PET) and whole-body low-dose X-ray computed tomography (CT). Results: There was a two-fold higher proportion of patients who reported one or more flare-ups on PBO 17/24 (71%) compared with GAR 7/20 (35%). Clinicians reported a four-fold higher proportion of patients experiencing one or more flare-ups on PBO 10/24 (42%) compared with GAR 2/20 (10%). Overall rates of flare-up events were two-fold higher on PBO vs. GAR (1.4 vs. 0.65 events/patient/28 weeks) for patient-reported events and eight-fold higher on PBO vs. GAR by clinician report (0.83 vs. 0.10 events/patient/28 weeks). Most flare-ups occurred on the extremities and back; pain was the most commonly reported symptom. Patient-reported flare-ups on PBO were more frequently reported as severe (29.4%) compared with GAR (7.7%). Among subjects with at least 12 weeks of follow-up from start of patient-reported flare-up, development of new HO near the site was 5/27 (18.5%) on PBO and (0%) on GAR. Of all new HO lesions, 41% on PBO and 0% on GAR occurred with spatial and temporal relation to flare-up. Conclusions: Approximately two-thirds of patients on PBO reported flare-ups over 28 weeks. GAR was associated with reductions in frequency and severity of flare-ups. Fewer than 20% of patient-reported flare-ups were associated with new HO, indicating frequent discordance of these phenomena, and compatible with previous reports. GAR’s ability to reduce patient- and clinician-reported flare-ups, as well as new HO lesions may provide an important therapeutic option.